Compare Geo Group Inc (The) REIT (GEO) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Geo Group Inc (The) REIT vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Geo Group Inc (The) REIT trades at $30.88 (market cap $4.24B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Geo Group Inc (The) REIT is far larger — about 4.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Geo Group Inc (The) REIT is trading nearer its 52-week high, Maravai LifeSciences Holdings Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Geo Group Inc (The) REIT for 6 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| GEO | MRVI | |
|---|---|---|
Market Cap | $4.24B | $972.90M |
Volume | 1,580,830 | 4,325,710 |
Sector | Industrials | Health |
52-Week High | $32.77 | $9.00 |
52-Week Low | $13.26 | $2.83 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $5.79B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GEO trades at $32.19, up 1.45% today, with a bullish technical signal from moving averages. Recent earnings beats in Q1 and Q2 2026, alongside a net income margin of 10.31% and ROE of 20.11%, highlight strong profitability. The company recently sold its Adelanto facilities for $950 million and increased its share repurchase authorization to $1.25 billion, signaling financial strength and shareholder returns.
The outlook is positive, supported by analyst consensus (66.7% buy ratings) and recent Zacks upgrades to Strong Buy. Key opportunities include earnings momentum and strategic asset sales, while risks involve debt management and potential regulatory scrutiny. The stock's valuation, with a P/E of 15.18, appears reasonable given growth prospects.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Geo Group Inc (The) REIT
The GEO Group provides correctional, detention, and community reentry services. Its operations include secure facilities, electronic monitoring, and support programs for individuals in the criminal-justice system.
Read more on GEO →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
